Notably, studies in hepatocellular carcinoma, prostate cancer, melanoma, and lung cancer have demonstrated how lactylation drives specific resistance phenotypes, such as stabilizing Insulin-like Growth Factor 2 mRNA-Binding Protein 3 (IGF2BP3), promoting Wnt/β-catenin signaling, or expanding Tregs [62,73,76,77]. This evidence concerns the gene IGF2BP3 and hepatocellular carcinoma.